KRAS-mutant colorectal cancer cell lines cause a prothrombotic state through the upregulation of thrombin: experimental study

  • 0Department of General Surgery, Yan'an Hospital Affiliated to Kunming Medical University, Kunming.

|

|

Summary

This summary is machine-generated.

KRAS-mutant colorectal cancer cells increase platelet aggregation and thrombin expression, contributing to a prothrombotic state. This cellular hypercoagulability is linked to poor prognosis in colorectal cancer patients.

Area Of Science

  • Oncology
  • Hematology
  • Molecular Biology

Background

  • Colorectal cancer (CRC) prognosis is linked to KRAS genotype and a prothrombotic state.
  • Hypercoagulability and cancer-related thrombosis are significant poor prognostic factors in CRC.
  • Cellular-level confirmation of the KRAS-CRC prothrombotic correlation is lacking.

Purpose Of The Study

  • To assess platelet aggregation rate induced by CRC cells with varying KRAS genotypes.
  • To evaluate thrombin expression in CRC cells under different KRAS statuses.
  • To explore the association between KRAS genotype and hypercoagulability at the cellular level.

Main Methods

  • Platelet aggregation rate assays were performed.
  • Western blotting analyzed thrombin expression.
  • Four CRC cell lines (RKO, HCT116, SW480, SW620) with different KRAS genotypes were utilized.
  • Tissue factor (FVIIa/TF) and thrombin inhibitors were used to investigate pathways.

Main Results

  • KRAS-mutant CRC cells significantly increased maximal platelet aggregation (34.7%-63.8%).
  • Metastatic SW620 cells showed higher aggregation rates than primary SW480 cells.
  • RKO cells exhibited lower thrombin expression compared to other KRAS-mutant lines.
  • Thrombin inhibitors more significantly reduced platelet aggregation in KRAS-mutant cells.

Conclusions

  • KRAS-mutant CRC cell lines demonstrate increased hypercoagulability.
  • Upregulated thrombin expression, primarily via the TF-thrombin pathway, drives this prothrombotic state.
  • KRAS genotype influences cellular prothrombotic potential in colorectal cancer.